CDC Models Show Scaling Up ART For HIV Treatment Can Save Money Over Time

During a webinar Thursday hosted by the Health Global Access Project, AVAC, and amfAR (The Foundation for AIDS Research), John Blandford, chief of CDC’s Division of Global HIV/AIDS Health Economics, Systems and Integration Branch, presented findings showing “that scaling up antiretroviral therapy (ART) for HIV/AIDS treatment and prevention in the developing world not only saves lives, but saves money too,” the Center for Global Health Policy’s “Science Speaks” blog reports. According to the blog, “[Blandford] and his team of colleagues have found that cost savings from averted negative outcomes offset a major portion of the cost of treatment over time.” The blog quotes Blandford saying, “Based on [WHO] standards, ART should be considered highly cost-effective in almost every country in sub-Saharan Africa” (Mazzotta, 1/27).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.